Brontictuzumab: Ph Ib discontinued

OncoMed said it will discontinue an open-label, dose-escalation, U.S. Phase Ib trial in mCRC patients after data showed that third-line treatment with IV brontictuzumab plus Lonsurf trifluridine/tipir...